Merck & Co Inc (FRA:6MK)
€ 92.9 -0.2 (-0.21%) Market Cap: 236.96 Bil Enterprise Value: 261.27 Bil PE Ratio: 21.36 PB Ratio: 5.93 GF Score: 78/100

Merck & Co Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 10:15PM GMT
Release Date Price: €72.1 (+3.07%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon, everybody. I'm Chris Schott at JPMorgan. And it's my pleasure to be introducing Merck today as we wrap up day 1 of the 40th Annual JPMorgan Healthcare Conference.

From the company, we have Rob Davis, the company's CEO; as well as Dean Li, President of Merck Research Labs. So Rob and Dean, Happy New Year. Great speaking with you today, and I look forward to the presentation.

Before I turn it over to Rob, I did want to mention, if anyone wants to ask a question during the Q&A portion of this, feel free to submit that through the Ask a Question button, and I'll work those into my Q&A as we go through.

With that, let me turn the call over to Rob to run through the presentation.

Robert M. Davis
Merck & Co., Inc. - President, CEO & Director

Well, great. Thanks, Chris, and good evening, everyone. I'm excited to be here with Dean to share with you our thoughts on why we're so confident about our ability to deliver short

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot